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Background: Armed conflict may increase the risk of HIV and other pathogens among injecting drug users (IDUs);
however, there are few prospective studies. This study aimed to measure incidence and potential predictors,
including environmental events and needle and syringe distribution and collection program (NSP) use, of hepatitis
C virus (HCV) and HIV among IDUs in Kabul, Afghanistan.
Methods: Consenting adult IDUs completed interviews quarterly in year 1 and semi-annually in year 2 and HCV
and HIV antibody testing semi-annually through the cohort period (November 2007–December 2009). Interviews
detailed injecting and sexual risk behaviors, NSP service use, and conflict-associated displacement. Quarters with
peak conflict or local displacement were identified based on literature review, and key events, including insurgent
attacks and deaths, were reported with simple counts. Incidence and predictors of HCV and HIV were measured
with Cox proportional hazards models.
Results: Of 483 IDUs enrolled, 385 completed one or more follow-up visits (483.8 person-years (p-y)).
All participants were male with a median age of 28 years and a median duration of injecting of 2 years.
Reported NSP use among the participants ranged from 59.9 to 70.5 % in the first year and was 48.4 and
55.4 % at 18 and 24 months, respectively. There were 41 confirmed deaths, with a crude death rate of
93.4/1000 p-y (95 % confidence interval (CI) 67.9–125) and overdose as the most common cause. HCV and
HIV incidence were 35.6/100 p-y (95 % CI 28.3–44.6) and 1.5/100 p-y (95 % CI 0.6–3.3), respectively. Changing
from injecting to smoking was protective for HCV acquisition (adjusted hazard ratio (AHR) = 0.53, 95 % CI
0.31–0.92), while duration of injecting (AHR = 1.09, 95 % CI 1.01–1.18/year) and sharing syringes (AHR = 10.09,
95 % CI 1.01–100.3) independently predicted HIV infection.
Conclusion: There is high HCV incidence and high numbers of reported deaths among male Kabul IDUs
despite relatively consistent levels of harm reduction program use; peak violence periods did not
independently predict HCV and HIV risk. Programming should increase awareness of HCV transmission and
overdose risks, prepare clients for harm reduction needs during conflict or other causes of displacement, and
continue efforts to engage community and police force support.
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The effects of armed conflict and displacement on sexual
and blood-borne pathogen infection are complex, with
multiple and potentially variable outcomes [1, 2]. Using
HIV as an example, systematic reviews of countries
where HIV is predominantly sexually transmitted indicate
that prevalence among communities of individuals fleeing
armed conflict is largely equivalent to or lower than
surrounding native communities and that population-
level HIV prevalence is generally lower in countries
affected by wide-scale armed conflict [3, 4]. However,
there is substantial variability in HIV prevalence
trends between studies conducted in refugee settle-
ments, and some data suggest sexual violence is asso-
ciated with HIV infection among displaced women in
specific contexts [3, 5]. Comparatively, there is little
information regarding impact of conflict in settings
where HIV or other pathogens like hepatitis C virus
(HCV) transmission is predominantly through inject-
ing drug use [6, 7]. The existing evidence base is con-
sidered weak due to lack of comparison populations
in assessing levels of risk behavior; limited analysis of
individual, network, or environmental factors; and
lack of interventions tailored to conflict settings [6].
An illustrative case is Afghanistan, where security
has deteriorated since 2006 and injecting as the route
of drug administration has become normative in the
recent years [8–10]. Key events shaping this context in-
clude poor governance and increasing insecurity resulting
in conditions favoring unchecked opiate production and,
potentially, consumption [11, 12]. Resultant insecurity has
increased internal displacement, generally to urban
areas with infrastructures already overtaxed by return-
ing refugees, some of whom were drug users [13].
Thus, the Kabul context from 2007 to 2009, the time
period during which this observational injecting drug
user (IDU) cohort was conducted, was impacted by
overcrowding, limited social services, high unemploy-
ment, and increasing insurgent attacks, leading to
frayed family support structures in an environment
with inexpensive, widely available opiates [8, 14].
Within this context, concentrated HCV and HIV
epidemics among IDUs have been reported in several
Afghan cities [8, 15–17]. However, these assessments
cannot infer causality for infection or measure con-
textual changes related to conflict, harm reduction
program use, and HCV or HIV risk [18, 19]. Harm
reduction and drug dependency treatment services in-
creased in number and scope during the same period
and may have offset risk of HCV or HIV [20, 21].
This study aims to estimate HCV and HIV incidence
and modifying factors, including civil insecurity and
harm reduction programming, among IDUs in Kabul,
Afghanistan.Methods
Setting
Kabul, the Afghan capital, contained 84.1 % of 1350
IDUs enumerated in a 2006 mapping survey [22]. During
the study period of June 2007 through December 2009,
harm reduction programming in Kabul expanded by
both number of programs and range of provided ser-
vices; by the end of 2009, programs routinely provided
drop-in centers, motivational counseling, washing facil-
ities, medical care, and testing for HIV, HCV, and other
infections. Some programs offered field outreach activ-
ities (generally needle and syringe distribution and col-
lection programs (NSPs)), meals, and night shelter [21].
At the initiation of the study, three harm reduction pro-
grams and two no-cost and multiple private for-profit
drug dependence treatment programs were operating in
Kabul. At the end of the study, there were five harm re-
duction programs operating, of which four had NSPs.
Harm reduction programs had only recently started
field-based naloxone distribution in the last year of the
study, while distribution of unused injecting supplies
(e.g., alcohol swab, gauze, and cooker) in addition to
syringes did not occur until after study completion. Opi-
oid substitution therapy was initiated in the last year of
the study as one pilot program in Kabul; expansion ef-
forts remain fraught [14]. Insurgent attacks increased
sharply in Kabul throughout the study period (95 in
2006 to 175 in 2009) [23].
Participant eligibility
Participants were enrolled between June 2007 and
March 2009 with follow-up through December 2009.
Eligibility was limited to IDUs who were aged ≥18 years;
reported injecting drugs within the prior 30 days; residing
in Kabul; Dari or Pashto speakers; and able to provide
informed consent. The protocol was approved by the
institutional review boards of the Afghan Ministry of
Public Health, Columbia University and the University
of California San Diego.
Measures
Primary outcome measures for this analysis were inci-
dent HCV and HIV infection. HCV seroconversion was
defined as having newly reactive HCV antibody (HCV
Ab) by a rapid diagnostic test (RDT) confirmed by either
detectable HCV viremia or HCV Ab. HIV seroconver-
sion was defined as confirmed HIV-1 antibody.
Baseline variables included in this analysis were socio-
demographic indicators and variables regarding drug use
history and conflict-related events (e.g., age and country
of initiating injecting, initiating injecting while a refu-
gee). Interval data analyzed included arrests, incarcer-
ation, employment, and homeless status. Interval drug
use behaviors included were frequency and duration of
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syringes or injecting works (e.g., filters, spoons), khoon
bozee (booting), syringe re-use, and perceived difficulty
obtaining clean syringes. Interval NSP use was measured
in three ways: any use during the prior 3 months,
current use, and discontinuing NSP use. Sexual risk be-
haviors queried were sex with female sex workers, sex
with other males, and any condom use. Other interval
events queried included drug dependence treatment,
symptoms suggestive of sexually transmitted infection
(e.g., dysuria, penile discharge, and/or genital ulcers or
warts), and travel outside Afghanistan during the follow-
up period.
Variables representing peak conflict periods (the two
quarters with the highest number of insurgent attacks)
and the quarters surrounding former Russian Cultural
Center (RCC) closure (February–May 2009) were gener-
ated for analysis. Conflict was quantified by enumerating
anti-government attacks in Kabul Province by quarter
[23]. For a comparison, an event with displacement
resulting not from violence or conflict but from an orga-
nized administrative action was also analyzed. The RCC,
known as khana-e-elm-o-farhang, was a dilapidated
building in West Kabul that informally housed between
200–300 drug users and displaced persons until early
2009, when police closed the site with resultant drug
user displacement. This closure was pre-announced to
occupants and enforced by police patrols without re-
ported excess use of force. Serious events (e.g., deaths,
police action) reported by the participants were recorded
in field notes and verified where possible. Deaths were
generally reported spontaneously by fellow participants,
other drug users, or harm reduction workers, though
study staff would inquire about the disposition of people
not seen recently among members of their social net-
work, which occasionally elicited a reported demise. Fol-
lowing an initial report, a second confirmatory report
was required to ensure the correct person was identified
as a death case and to obtain the maximum amount of
information about cause of death. Cause of death was
routinely queried on report but some deaths were re-
ported with no clear cause or the attributed cause could
not be verified by a second report. Only death data con-
firmed by two separate reports are presented.
Data collection and laboratory methods
Data collection has been previously described in an ana-
lysis of baseline data [24]. Briefly, the participants were
recruited consecutively from areas of known drug user
congregation and through harm reduction programs on
scheduled days loosely apportioned by number of IDUs
present at those locations, in a variant of time-location
sampling. Recruitment sites were initially determined
through formative work and through harm reductionprograms [25], with locations adjusted monthly based on
information from the participants, the harm reduction
field workers, and pharmacists of new areas of congrega-
tion. There was no set sample size for recruitment at a
given site. Sites were distributed throughout Kabul city,
with most sites in the western section of the city, con-
sistent with reported and confirmed IDU presence
throughout the study period.
For follow-up visits, the participants were met in the
field by the study staff and invited to the study office or
collaborating harm reduction center for private inter-
view. The study staff comprised former harm reduc-
tion workers known to the drug user community and
medical professionals (one physician, one lab technician,
and one counselor) with experience working with drug
users. The staff members were trained in human subject
research, interview techniques, and voluntary counseling
and testing and also the shadowed field workers in oper-
ating harm reduction programs in Afghanistan and Iran
to gain additional familiarity with the drug-using com-
munity and understand NSP implementation. The study
staff members were responsible for all aspects of partici-
pant activity, including recruitment, though collaborat-
ing harm reduction programs also referred clients for
potential participation without compensation.
The participants were assigned a unique study number
not linked to any national identifier at enrollment and
provided a laminated number “charm” on a thick yarn
necklace for them to keep with them for identification
through the study period. The participants also provided
their preferred name, often a street nickname, to the
study staff, who kept a record linking number and name
that was stored in a locked secure location when not in
use by the study staff in the field. Many participants
interacted with the study staff during weekly field visits
to the sites they regularly frequented and were well-
known to the study staff. However, there were some par-
ticipants who were not encountered regularly and who
provided a street nickname that changed during the
study period, making definitive participant identification
challenging. The participants not well-known to the
study staff were asked to present their study number to
the staff prior to proceeding with follow-up visit
activities.
Following definitive identification, the participants
completed the interviewer-administered questionnaire,
received pre-test counseling, and underwent a whole-blood
RDT for antibodies to HCV and HIV-1 (SD Bioline, Stand-
ard Diagnostics, Kyonggi-do, South Korea). The partici-
pants with reactive RDT results provided intravenous
specimens, where possible, for confirmatory testing. HCV
was confiemd by presence of viremia, tested with polymerase
chain reaction (Amplicor, Roche Diagnostics, Mannheim,
Germany) or, in absence of viremia, HCV antibody
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RIBA 3.0 SIA, Chiron Company, Emeryville, California).
HIV seroconversion was confirmed with a positive
Western blot test (HIV Blot 2.2, Genelabs, Singapore).
The participants completed their visit with post-test
counseling. Follow-up visits occurred at 3, 6, 9, 12, 18,
and 24 months, with serologic testing every 6 months.
Treatment referrals were provided for the participants
with confirmed HCV and HIV who received results. The
participants received in-kind compensation of meals and
transportation to and from study visits and injecting and
sexual risk reduction supplies, including disposable
syringes, alcohol pads, naloxone, and hepatitis B vaccin-
ation (for those with non-reactive baseline hepatitis B
surface antibody and antigen RDT results).Analysis
Descriptive statistics were generated for participants
contributing interval data and compared to those lost to
follow-up with Chi-square tests, t tests, or exact tests, as
appropriate. All longitudinal analysis used time defined
by visit date. The key outcome measures, HCV and HIV
incidence, were calculated with corresponding binomial
(HCV) and Poisson (HIV) confidence intervals. Only in-
dividuals seronegative for HCV or HIV antibody at base-
line with follow-up serologic testing were included in
incidence and risk factor analyses.
Risk factors for each outcome were separately assessed
using Cox proportional hazards models. First, each out-
come was compared to baseline and time-varying predic-
tors and environmental event variables (e.g., former RCC
closure) with bivariate Cox regression analysis. Next, fac-
tors associated with each outcome at the p ≤ 0.20 level in
bivariate analysis were eligible for entry into multivariable
models. For models with more than one predictor, likeli-
hood ratio test was used to select the best fitting model.
Confounders were defined as variables entering the multi-
variable model that altered the hazard ratio (HR) in bivari-
ate analysis by >10 % for a statistically significant
predictor variable. Final models included predictors from
the model with best fit and any identified confounders.
For HCV, a separate analysis to better delineate the
impact of peak violence on acquisition was per-
formed, as the second peak violence period occurred
within 4 months of study closure, potentially exclud-
ing cases resulting from behaviors during that period.
A forward-lagged variable for peak violence was cre-
ated for quarter 7, and the quarter during which cases
acquired during the peak violence period (Quarter 5)
would have been detectable. Statistical significance
was defined as two-sided p ≤ 0.05. All analysis was
performed with Stata 11.0 (Stata Corporation, College
Station, Texas).Results
Participant characteristics and cohort events
Of 483 participants, 386 (79.9 %) completed one or
more follow-up visits (438.8 person-years (p-y)). The
participants could present for any follow-up visit within
a specified time interval, and missing one interval visit
did not preclude later eligibility. Follow-up rates were
83.9 % (323/385), 77.9 % (300/385), 69.6 % (265/381),
69.2 % (252/364), 55.6 % (153/275), and 38.7 % (65/168)
of those eligible at 3, 6, 9, 12, 18, and 24 months, re-
spectively. The participants lost to follow-up were signifi-
cantly less likely to have prevalent HCV or have initiated
injecting within the last year and more likely to have initi-
ated injecting as a refugee or outside Afghanistan, be
homeless, or have injected for a longer duration (Table 1).
HCV incidence, insurgent attacks, and RCC closure
during the study period are summarized in Fig. 1. Of
415 participants eligible for hepatitis B vaccination, 95.7,
64.1, and 30.8 % received first, second, and third doses,
respectively. Half or more of the participants reported
NSP use at any time during the cohort period; NSP use
ranged from 59.9 to 70.5 % in the first year of participa-
tion and was 48.4 and 55.4 % at 18 and 24 months, re-
spectively. The crude death rate was 93.4/1000 p-y (95 %
confidence interval (CI) 67.9–125); of 41 confirmed
deaths, 43.9 % (n = 18) were reported to result from over-
dose. Other reported causes of death included exposure
during inclement weather or snow (n = 6), femoral or other
abscess (n = 3), trauma (e.g., hit by car, fell down stairs,
and beaten by police) (n = 3), chest infection (n = 2), in-
ternal bleeding (n = 1), and unknown (n = 8).
HCV and HIV incidence and risk factors
Of 333 participants contributing follow-up data at visits
with serologic testing, 191 were at risk for HCV infec-
tion and contributed 211 p-y, while 316 were at risk for
HIV infection, contributing 391 p-y for analysis. The in-
cidence and median time to infection for HCV were
35.6 cases/100 p-y (95 % CI: 28.4–44.6) and 9.3 months
and, for HIV, were 1.5 cases/100 p-y (95 % CI: 0.6–3.3)
and 18.3 months.
Risk of HCV acquisition increased with any NSP use,
while transitioning from injecting to smoking, sharing
injecting works, NSP discontinuation, and, marginally,
exposure to peak conflict periods were negatively pre-
dictive in bivariate analysis (Table 2). No sexual risk be-
havior or other conflict-related variables were significant
predictors in bivariate analysis (data not shown). To fur-
ther describe the relationship between conflict and HCV
acquisition, a lagged variable restricted to 6 months fol-
lowing the quarter with the greatest number of insurgent
attacks was assessed and was not significant (HR = 0.97,
95 % CI 0.56–1.70). In multivariable modeling, only
changing from injecting to smoking remained protective
Table 1 Differences between male injecting drug users retained
and lost to follow-up in Kabul, Afghanistan, 2007–2009
Baseline-only
group (n = 97)
Cohort group
(n = 386)
Variable Median (IQR) Median (IQR) p value
Age (years) 27, (24–32) 28 (24–35) 0.10
Duration of injecting
(years)
1 (0–4) 2 (1–6) <0.01
Age initiated injecting
(years)
25 (21–28) 24 (21–29) 0.92
Level of education
(years)
5 (2–9) 5 (0–8) 0.69
Variable n (%) n, (%) p value
Ever married 51 (53) 173 (45) 0.17
Born in Afghanistan 85 (88) 333 (87) 0.73
Lived outside Afghanistan
in the last 5 years
60 (62) 250 (65) 0.51
Homeless at enrollment 9 (9) 99 (26) <0.01
Employed at enrollment 11 (11) 45 (12) 0.91
Prior incarceration 60 (62) 242 (63) 0.79
Initiated injecting in
Afghanistan
76 (78) 245 (64) <0.01
Initiated injecting as a
refugeea
18 (20) 124 (36) <0.01
Initiated injection within
the last 12 months
33 (34) 78 (20) <0.01
Shared needles/syringes
within 3 months of
enrollment
(baseline report)
2 (2) 70 (8 0.06
Shared injecting
equipment within
3 months of enrollment
(baseline report)
26 (27) 106 (28) 0.90
Ever inject/re-aspirate
blood
70 (72) 267 (69) 0.64
NSP service use at
enrollment
54 (56) 204 (53) 0.67
Receive prior addiction
treatment
10 (10) 60 (16) 0.18
HCV infection at baseline 18 (19) 156 (40) <0.01
HIV infection at baseline 1 (1) 9 (2) 0.70
HIV human immunodeficiency virus, NSP needle and syringe distribution and
collection program, IQR interquartile range, n number
aOf 437 participants who were ever refugees
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Sharing injecting works confounded this relationship, in-
creasing risk by 6 %.
HIV acquisition significantly increased with duration
of injecting and sharing syringes in bivariate and multi-
variate Cox regression models (Table 2). The model with
both predictors indicated HIV risk increased by 9 %/yearwith duration of injecting (adjusted hazard ratio
(AHR) = 1.09, 95 % CI 1.01–1.18) and 16-fold for
sharing syringes (AHR = 16.1, 95 % CI 1.68–153.1), as
duration of injecting increased risk of HIV secondary
to sharing syringes. The multivariate model was then
adjusted for interval NSP use, which decreased HIV
risk secondary to sharing syringes (HR = 11.23 to
AHR = 7.19 in model including sharing syringes and
interval NSP use); in the final adjusted model, sharing
syringes increased HIV risk 11-fold (Table 2). No con-
founders were identified for the association between dur-
ation of injecting and HIV acquisition. Of six new HIV
infections, five occurred in men with prevalent HCV,
while the remaining participant was diagnosed with inci-
dent HCV and HIV at the 6-month follow-up visit.
Discussion
The results of this study may contribute to evidence
concerning conflict and drug use and may inform pro-
gramming in Afghanistan and other conflict-affected set-
tings [6–8, 26–29]. Key findings include high HCV
incidence whose risk was reduced by half with cessation
of injecting, low HIV incidence, high death rates, and
relatively high rates of NSP use throughout the cohort
period.
HCV incidence was quite high, similar to rates re-
ported among other IDU populations in non-conflict
settings [30–35]. Change from injecting to smoking was
protective against HCV and may have been prompted by
desire to enter a drug dependence treatment program.
Spaces for no-cost inpatient treatment programs in
Kabul are limited and require 1 to 3 months of daily out-
patient counseling with demonstrated transition to
smoking preferred [9]. Motivation to enter a highly
coveted treatment program may have prevented HCV
infection, even in an environment where displacement
or violence may have favored transition to or continu-
ation of injecting [27–29]. These findings could also be
used for primary prevention programming by discour-
aging transition from smoking to injecting as a means of
preventing HCV acquisition.
Sharing injecting works negatively predicted HCV ac-
quisition in bivariate analysis but slightly increased risk
among those transitioning to smoking in the final model,
potentially representing an unreported resumption of
injecting. This finding requires further inquiry as HCV
transmission resulting from the use of contaminated inject-
ing paraphernalia is well-established [36]. We hypothesize
that increased knowledge surrounding risks of sharing
works without availability of these items through harm
reduction programs during the study period may have
resulted in under-reporting of ongoing sharing. Further,
HCV was not as widely emphasized as a risk of injecting


































Fig. 1 Insurgent attacks and incident hepatitis C cases among male injecting drug users in Kabul, Afghanistan, June 2007–December
2009 (n = 191)
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treatment offerings as HIV treatment for IDUs is avail-
able through one harm reduction program in Kabul
while HCV treatment is not available in the public sec-
tor and remains very expensive (personal communica-
tion, Dr. H. Mansoor). Underestimation of HCV cases
may have occurred through attrition from baseline or
differential drop-out as participants at risk for HCV
were increasingly lost to follow-up compared to those
with prevalent infection.
HIV incidence was comparatively low, in contrast to
Pakistan, a country affected by violent attacks, and to
predictions for conflict-affected contexts [6, 37]. LowTable 2 Factors predictive of HCV and HIV among male injecting dr
Variable HCV (n = 191, 211 p-y) HCV
HR, (95 % CI) AHR, (9
Duration of injecting use
Sharing of syringes/needles
Sharing of injecting supplies 0.56, (0.35–0.90)
Any NSP use during interval 1.72, (1.07–2.76)
Interval NSP discontinuation 0.61, (0.38–0.98)
Changed from injecting to smoking 0.47, (0.29–0.77) 0.53, (0
Peak quarters of attack exposurec 0.65, (0.40–1.04)*
AHR adjusted hazard ratio, CI confidence interval, HCV hepatitis C virus, HIV human
and distribution program, p-y person-years
*Marginally significant (p = 0.07)
aMultivariate analysis controlled for confounder interval NSP use (11.23 to 7.19)
bAnalysis controlled for cofounder interval sharing injecting works (0.47 to 0.53)
cPeak quarters of attack refer to quarters 5 and 9 of the study, the two quarters witHIV incidence may reflect lower per-act risk due to
known lower prevalence among Kabul IDUs [17, 24].
HIV acquisition increased with duration of injecting and
with interval sharing of syringes, both established risk
factors by international consensus and also associated with
prevalent infection in this cohort [24, 37–40]. Recent NSP
use reduced HIV risk attributable to syringe sharing, yet
significantly increased HCV risk in bivariate analysis.
We hypothesize that these disparate results were due to
environmental influences. Most new HCV infections
were detected in quarters 7–9 (February–September,
2009), representing the time surrounding and immedi-
ately following RCC closure. During this period ofug users in Kabul, Afghanistan, 2006–2009
HIV (n = 316, 391 p-y) HIV
5 % CI) HR, (95 % CI) AHR, (95 % CI)
1.08, (1.00–1.17) 1.09, (1.01–1.17)a
11.23, (1.29–98.0) 10.08, (1.01–100.3)a
.31–0.92)b 0.23, (0.03–1.93)
immunodeficiency virus, HR hazard ratio, NSP needle and syringe collection
h the largest number (142/415 total) of insurgent attacks in Kabul province
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particularly field-based services like NSP, was more
likely, potentially leading to unreported new-onset syr-
inge sharing or other risky injecting behaviors. Further
investigation is needed to determine NSP service cover-
age and reasons for discontinuation in this challenging
setting. The negative association between exposure to
violence and HCV acquisition in bivariate analysis po-
tentially reflects IDUs secluding themselves alone or
within well-established networks wherein new transmis-
sion is unlikely, even with potential increase in individ-
ual risk behaviors. Risk factors for HIV should be
interpreted with caution due to very low incidence.
Deaths were common and under-reporting was likely,
though the crude death rate was high compared to that
reported for Afghan males aged between 20 and
59 years (10.99/1000 p-y) [41]. Study representatives
were informed of approximately 30 additional deaths
that could not be confirmed. These data should be
interpreted with caution as exact cause of death was
subject to the same limitations as enumerating deaths
due to lack of a reliable death registry and challenges
inherent to tracking health outcomes in this marginal-
ized population. For similar reasons, we did not analyze
associations between environmental events and re-
ported date of death. Overdose was the most common
reported cause of death. During the cohort period,
field-based distribution of naloxone was not routinely
provided by NSPs until 2009, though it was through
the study. NSPs expanded the range of distributed
products during the cohort period to include both na-
loxone and injecting paraphernalia beyond syringes;
impact of this change on overdose and HCV inci-
dence should be assessed.
Several additional limitations must be considered.
First, the cohort had low follow-up rates, particularly in
the second year. This study was very challenging oper-
ationally as approximately 20 % of the participants were
homeless and many came to Kabul as a first point of re-
patriation, potentially then moving to home provinces,
making it difficult to find the same individual on a
regular basis. The study staff knew many participants
only by a street nickname, which could change over
time, potentially motivated by fear of police action. Fur-
ther, particularly following RCC closure, police action
allegedly led to repeated scattering of the participants
throughout Kabul, making wide sampling efforts and
regular follow-up difficult. Migration within and out-
side Kabul, unconfirmed deaths, and incarceration also
likely contributed to high attrition. Efforts to equally
distribute participant enrollment between known sites
of drug user congregation throughout Kabul were
based on numbers that varied widely throughout the
cohort period. We attempted to mitigate this effectby regularly consulting the outreach workers and the
participants with esteemed standing in their social
groups as to where to reach current and potential
participants, but congregation sites frequently changed
without warning. Thus, there may have been bias to-
ward selecting individuals accessing harm reduction
programs and returning to the same congregation
sites, with resultant higher reported NSP use rates.
Some reporting or recall bias may have been present;
to minimize this, the participants were asked about
behaviors in the last 3 months and the first year com-
prised quarterly follow-up. Due to low literacy, ques-
tionnaires were administered by study representatives,
with possible resultant socially desirable response.
Audio computer-assisted self-interview was not feas-
ible in this setting.
In summary, while there are important limitations,
data indicate Kabul IDUs are caught in the crossfire
of environmental changes fostering high HCV inci-
dence and death rates. Growing instability, displace-
ment, and increasing competition for resources in
Kabul and limited progress toward improving key
environmental elements indicate need for different
approaches to harm reduction in this context. Harm
reduction and drug dependence treatment program-
ming should increase emphasis on prevention pro-
gramming for HCV and overdose and develop and
test models for service provision or client prepared-
ness during times of displacement to prevent field-
based harm reduction service interruption as well as
to work with clients to transition from injecting to
smoking and prevent transition to injection among
smokers. NSP programs are to be commended for rela-
tively high sustained levels of service provision in this
challenging setting and for ongoing educational efforts
aimed at aligning policing and community support with
harm reduction. These interventions, particularly with
police, should continue but adaptability of, expansion of,
and improved services within harm reduction programs
are also indicated to enable drug users to cope with
ongoing conflict in this and similar contexts.
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